Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial: reply

Rheumatology (Oxford). 2019 May 1;58(5):925-926. doi: 10.1093/rheumatology/kez054.

Authors

Geetabali Sircar¹, Rudra Prosad Goswami¹, Dipankar Sircar², Alakendu Ghosh¹, Parasar Ghosh¹

Affiliations

¹ Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata.
² Department of Nephrology, Institute of Postgraduate Medical Education and Research, Kolkata.

PMID: 30809671
DOI: 10.1093/rheumatology/kez054

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Murine-Derived
Cyclophosphamide
Humans
Lung Diseases*
Rituximab
Scleroderma, Diffuse*

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab
Cyclophosphamide